Chemical: Drug
perphenazine

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for perphenazine

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
VIP No VIP available No VIP available CYP2D6 *1 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *2 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *3 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *4 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *6 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *9 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *10 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *17 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *29 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *41 N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 extensive metabolizer genotype N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizer genotype N/A N/A N/A
VIP No Clinical Annotations available No Variant Annotations available
rs1065852 NC_000022.10:g.42526694G=, NC_000022.10:g.42526694G>A, NC_000022.11:g.42130692G=, NC_000022.11:g.42130692G>A, NG_008376.3:g.4300C=, NG_008376.3:g.4300C>T, NM_000106.5:c.100C=, NM_000106.5:c.100C>T, NM_001025161.2:c.100C=, NM_001025161.2:c.100C>T, NP_000097.3:p.Pro34=, NP_000097.3:p.Pro34Ser, NP_001020332.2:p.Pro34=, NP_001020332.2:p.Pro34Ser, NT_187682.1:g.53033G=, NT_187682.1:g.53033G>A, NW_004504305.1:g.53019A=, NW_004504305.1:g.53019A>G, NW_009646208.1:g.16258A=, NW_009646208.1:g.16258A>G, XM_005278353.1:c.100T=, XM_005278353.1:c.100T>C, XM_005278354.1:c.-1454C>T, XM_005278354.1:c.-1454T>C, XM_005278354.3:c.-1454C>T, XM_005278354.3:c.-1454T>C, XM_011529966.1:c.100C=, XM_011529966.1:c.100C>T, XM_011529967.1:c.100C=, XM_011529967.1:c.100C>T, XM_011529968.1:c.100C=, XM_011529968.1:c.100C>T, XM_011529969.1:c.37+605C>T, XM_011529969.1:c.37+605T>C, XM_011529970.1:c.100C=, XM_011529970.1:c.100C>T, XM_011529971.1:c.37+605C>T, XM_011529971.1:c.37+605T>C, XM_011529972.1:c.100C=, XM_011529972.1:c.100C>T, XM_011547541.1:c.-1454C>T, XM_011547541.1:c.-1454T>C, XM_011547750.1:c.37+605C>T, XM_011547750.1:c.37+605T>C, XM_011547751.1:c.-1114C>T, XM_011547751.1:c.-1114T>C, XM_011547756.1:c.42+469A>G, XM_011547756.1:c.42+469G>A, XM_011548819.1:c.-1454C>T, XM_011548819.1:c.-1454T>C, XP_005278410.1:p.Ser34=, XP_005278410.1:p.Ser34Pro, XP_011528268.1:p.Pro34=, XP_011528268.1:p.Pro34Ser, XP_011528269.1:p.Pro34=, XP_011528269.1:p.Pro34Ser, XP_011528270.1:p.Pro34=, XP_011528270.1:p.Pro34Ser, XP_011528272.1:p.Pro34=, XP_011528272.1:p.Pro34Ser, XP_011528274.1:p.Pro34=, XP_011528274.1:p.Pro34Ser, XR_430455.2:n.328+4A>G, XR_430455.2:n.328+4G>A, XR_952536.1:n.-1751A>G, XR_952536.1:n.-1751G>A, XR_952537.1:n.-1751A>G, XR_952537.1:n.-1751G>A, XR_952538.1:n.-1751A>G, XR_952538.1:n.-1751G>A, XR_952539.1:n.-1462A>G, XR_952539.1:n.-1462G>A, XR_952745.1:n.1257C=, XR_952745.1:n.1257C>T, rs117813846, rs58862176
G > A
SNP
P34S
No VIP available No Clinical Annotations available VA
rs11100483 NC_000004.11:g.141022317G>A, NC_000004.12:g.140101163G>A, NM_018717.4:c.468+51697C>T
G > A
SNP
No VIP available No Clinical Annotations available VA
rs11774231 NC_000008.10:g.6504316C>T, NC_000008.11:g.6646795C>T, NR_125386.1:n.70-19485G>A
C > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs16947 NC_000022.10:g.42523943A=, NC_000022.10:g.42523943A>G, NC_000022.11:g.42127941G=, NC_000022.11:g.42127941G>A, NG_008376.3:g.7051C=, NG_008376.3:g.7051C>T, NM_000106.5:c.886C=, NM_000106.5:c.886C>T, NM_001025161.2:c.733C=, NM_001025161.2:c.733C>T, NP_000097.3:p.Arg296=, NP_000097.3:p.Arg296Cys, NP_001020332.2:p.Arg245=, NP_001020332.2:p.Arg245Cys, NT_187682.1:g.50282A=, NT_187682.1:g.50282A>G, NW_004504305.1:g.50268G=, NW_004504305.1:g.50268G>A, NW_009646208.1:g.13507G=, NW_009646208.1:g.13507G>A, XM_005278353.1:c.742C=, XM_005278353.1:c.742C>T, XM_005278354.1:c.586C=, XM_005278354.1:c.586C>T, XM_005278354.3:c.586C=, XM_005278354.3:c.586C>T, XM_011529966.1:c.886C=, XM_011529966.1:c.886C>T, XM_011529967.1:c.886C=, XM_011529967.1:c.886C>T, XM_011529968.1:c.886C=, XM_011529968.1:c.886C>T, XM_011529969.1:c.742C=, XM_011529969.1:c.742C>T, XM_011529970.1:c.733C=, XM_011529970.1:c.733C>T, XM_011529971.1:c.742C=, XM_011529971.1:c.742C>T, XM_011529972.1:c.843+233C>T, XM_011529972.1:c.843+233T>C, XM_011547541.1:c.586C=, XM_011547541.1:c.586C>T, XM_011547750.1:c.742T=, XM_011547750.1:c.742T>C, XM_011547751.1:c.670T=, XM_011547751.1:c.670T>C, XM_011547756.1:c.-2094A>G, XM_011547756.1:c.-2094G>A, XM_011548819.1:c.586C=, XM_011548819.1:c.586C>T, XP_005278410.1:p.Arg248=, XP_005278410.1:p.Arg248Cys, XP_005278411.1:p.Arg196=, XP_005278411.1:p.Arg196Cys, XP_011528268.1:p.Arg296=, XP_011528268.1:p.Arg296Cys, XP_011528269.1:p.Arg296=, XP_011528269.1:p.Arg296Cys, XP_011528270.1:p.Arg296=, XP_011528270.1:p.Arg296Cys, XP_011528271.1:p.Arg248=, XP_011528271.1:p.Arg248Cys, XP_011528272.1:p.Arg245=, XP_011528272.1:p.Arg245Cys, XP_011528273.1:p.Arg248=, XP_011528273.1:p.Arg248Cys, XP_011545843.1:p.Arg196=, XP_011545843.1:p.Arg196Cys, XP_011546052.1:p.Cys248=, XP_011546052.1:p.Cys248Arg, XP_011546053.1:p.Cys224=, XP_011546053.1:p.Cys224Arg, XP_011547121.1:p.Arg196=, XP_011547121.1:p.Arg196Cys, XR_430455.2:n.-1930A>G, XR_430455.2:n.-1930G>A, XR_952745.1:n.2000+233C>T, XR_952745.1:n.2000+233T>C, rs117039205, rs57836231
A > G
SNP
R296C
No VIP available No Clinical Annotations available VA
rs17570753 NC_000008.10:g.6502359T>A, NC_000008.11:g.6644838T>A, NG_016619.1:g.243247T>A, NR_125386.1:n.70-17528A>T
T > A
SNP
No VIP available No Clinical Annotations available VA
rs2116971 NC_000016.10:g.82632534G>A, NC_000016.9:g.82666139G>A, NM_001220488.1:c.80+5397G>A, NM_001220489.1:c.45+5397G>A, NM_001220490.1:c.-509+5397G>A, NM_001220491.1:c.45+5397G>A, NM_001220492.1:c.45+5397G>A, NM_001257.4:c.45+5397G>A, XM_011522805.1:c.80+5397G>A, rs17261091
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2278773 NC_000002.11:g.46412422C>G, NC_000002.12:g.46185283C>G, NM_005400.2:c.*402C>G, XM_005264428.1:c.*402C>G, XM_005264429.1:c.*402C>G, XM_005264430.1:c.*402C>G, XM_006712050.2:c.*402C>G, XM_011532970.1:c.*402C>G, XM_011532971.1:c.*402C>G, XM_011532972.1:c.*402C>G, XM_011532973.1:c.*402C>G, XM_011532974.1:c.*402C>G, XM_011532975.1:c.*402C>G, XM_011532976.1:c.*402C>G, XM_011532977.1:c.*402C>G, XM_011532978.1:c.*402C>G, XM_011532979.1:c.*402C>G, XM_011532980.1:c.*402C>G, XM_011532981.1:c.*402C>G, XM_011532982.1:c.*402C>G, XM_011532983.1:c.*402C>G
C > G
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs28371706 NC_000022.10:g.42525772G>A, NC_000022.11:g.42129770G>A, NG_008376.3:g.5222C>T, NM_000106.5:c.320C>T, NM_001025161.2:c.320C>T, NP_000097.3:p.Thr107Ile, NP_001020332.2:p.Thr107Ile, NT_187682.1:g.52111G>A, NW_004504305.1:g.52097G>A, NW_009646208.1:g.15336G>A, XM_005278353.1:c.320C>T, XM_005278354.1:c.-532C>T, XM_005278354.3:c.-532C>T, XM_011529966.1:c.320C>T, XM_011529967.1:c.320C>T, XM_011529968.1:c.320C>T, XM_011529969.1:c.177C>T, XM_011529970.1:c.320C>T, XM_011529971.1:c.177C>T, XM_011529972.1:c.320C>T, XM_011547541.1:c.-532C>T, XM_011547750.1:c.177C>T, XM_011547751.1:c.-192C>T, XM_011547756.1:c.-265G>A, XM_011548819.1:c.-532C>T, XP_005278410.1:p.Thr107Ile, XP_011528268.1:p.Thr107Ile, XP_011528269.1:p.Thr107Ile, XP_011528270.1:p.Thr107Ile, XP_011528271.1:p.His59=, XP_011528272.1:p.Thr107Ile, XP_011528273.1:p.His59=, XP_011528274.1:p.Thr107Ile, XP_011546052.1:p.His59=, XR_430455.2:n.-101G>A, XR_952745.1:n.1477C>T, rs587777915, rs59604033
G > A
SNP
T107I
VIP No Clinical Annotations available No Variant Annotations available
rs28371725 NC_000022.10:g.42523805C>T, NC_000022.11:g.42127803C>T, NG_008376.3:g.7189G>A, NM_000106.5:c.985+39G>A, NM_001025161.2:c.832+39G>A, NT_187682.1:g.50144C>T, NW_004504305.1:g.50130C>T, NW_009646208.1:g.13369C>T, XM_005278353.1:c.841+39G>A, XM_005278354.1:c.685+39G>A, XM_005278354.3:c.685+39G>A, XM_011529966.1:c.985+39G>A, XM_011529967.1:c.985+39G>A, XM_011529968.1:c.985+39G>A, XM_011529969.1:c.841+39G>A, XM_011529970.1:c.832+39G>A, XM_011529971.1:c.841+39G>A, XM_011529972.1:c.844-169G>A, XM_011547541.1:c.724G>A, XM_011547750.1:c.841+39G>A, XM_011547751.1:c.769+39G>A, XM_011548819.1:c.724G>A, XP_011545843.1:p.Glu242Lys, XP_011547121.1:p.Glu242Lys, XR_952745.1:n.2001-169G>A, rs57124011, rs587777916
C > T
SNP
No VIP available CA VA
rs2842030 NC_000001.10:g.163040495G>T, NC_000001.11:g.163070705G>T, NG_023312.1:g.7100G>T, NM_001102445.2:c.335+1177G>T, NM_001113380.1:c.-1449G>T, NM_001113381.1:c.44+1177G>T, NM_005613.5:c.44+1177G>T
G > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs35742686 NC_000022.10:g.42524244delT, NC_000022.11:g.42128242delT, NG_008376.3:g.6750delA, NM_000106.5:c.775delA, NM_001025161.2:c.622delA, NP_000097.3:p.Arg259Glyfs, NP_001020332.2:p.Arg208Glyfs, NT_187682.1:g.50583delT, NW_004504305.1:g.50569delT, NW_009646208.1:g.13808delT, XM_005278353.1:c.631delA, XM_005278354.1:c.475delA, XM_005278354.3:c.475delA, XM_011529966.1:c.775delA, XM_011529967.1:c.775delA, XM_011529968.1:c.775delA, XM_011529969.1:c.631delA, XM_011529970.1:c.622delA, XM_011529971.1:c.631delA, XM_011529972.1:c.775delA, XM_011547541.1:c.475delA, XM_011547750.1:c.631delA, XM_011547751.1:c.559delA, XM_011547756.1:c.-1793delT, XM_011548819.1:c.475delA, XP_005278410.1:p.Arg211Glyfs, XP_005278411.1:p.Arg159Glyfs, XP_011528268.1:p.Arg259Glyfs, XP_011528269.1:p.Arg259Glyfs, XP_011528270.1:p.Arg259Glyfs, XP_011528271.1:p.Arg211Glyfs, XP_011528272.1:p.Arg208Glyfs, XP_011528273.1:p.Arg211Glyfs, XP_011528274.1:p.Arg259Glyfs, XP_011545843.1:p.Arg159Glyfs, XP_011546052.1:p.Arg211Glyfs, XP_011546053.1:p.Arg187Glyfs, XP_011547121.1:p.Arg159Glyfs, XR_430455.2:n.-1629delT, XR_952745.1:n.1932delA, rs45593132, rs60790764
T > -
T > T
indel
R259G
VIP No Clinical Annotations available No Variant Annotations available
rs3892097 NC_000022.10:g.42524947C=, NC_000022.10:g.42524947C>T, NC_000022.11:g.42128945C=, NC_000022.11:g.42128945C>T, NG_008376.3:g.6047G=, NG_008376.3:g.6047G>A, NM_000106.5:c.506-1A>G, NM_000106.5:c.506-1G>A, NM_001025161.2:c.353-1A>G, NM_001025161.2:c.353-1G>A, NT_187682.1:g.51286C=, NT_187682.1:g.51286C>T, NW_004504305.1:g.51272T=, NW_004504305.1:g.51272T>C, NW_009646208.1:g.14511C=, NW_009646208.1:g.14511C>T, XM_005278353.1:c.363-2A>G, XM_005278353.1:c.363-2G>A, XM_005278354.1:c.207-2A>G, XM_005278354.1:c.207-2G>A, XM_005278354.3:c.207-2A>G, XM_005278354.3:c.207-2G>A, XM_011529966.1:c.506-1A>G, XM_011529966.1:c.506-1G>A, XM_011529967.1:c.506-1A>G, XM_011529967.1:c.506-1G>A, XM_011529968.1:c.506-1A>G, XM_011529968.1:c.506-1G>A, XM_011529969.1:c.363-2A>G, XM_011529969.1:c.363-2G>A, XM_011529970.1:c.353-1A>G, XM_011529970.1:c.353-1G>A, XM_011529971.1:c.363-2A>G, XM_011529971.1:c.363-2G>A, XM_011529972.1:c.506-1A>G, XM_011529972.1:c.506-1G>A, XM_011547541.1:c.207-2A>G, XM_011547541.1:c.207-2G>A, XM_011547750.1:c.363-2A>G, XM_011547750.1:c.363-2G>A, XM_011547751.1:c.290-1A>G, XM_011547751.1:c.290-1G>A, XM_011547756.1:c.-1090C>T, XM_011547756.1:c.-1090T>C, XM_011548819.1:c.207-2A>G, XM_011548819.1:c.207-2G>A, XR_430455.2:n.-926C>T, XR_430455.2:n.-926T>C, XR_952745.1:n.1663-1A>G, XR_952745.1:n.1663-1G>A, rs1800716, rs28371711, rs60082401, rs606231227
C > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs5030655 NC_000022.10:g.42525086delA, NC_000022.11:g.42129084delA, NG_008376.3:g.5908delT, NM_000106.5:c.454delT, NM_001025161.2:c.353-140delT, NP_000097.3:p.Trp152Glyfs, NT_187682.1:g.51425delA, NW_004504305.1:g.51411delA, NW_009646208.1:g.14650delA, XM_005278353.1:c.363-141delT, XM_005278354.1:c.155delT, XM_005278354.3:c.155delT, XM_011529966.1:c.454delT, XM_011529967.1:c.454delT, XM_011529968.1:c.454delT, XM_011529969.1:c.311delT, XM_011529970.1:c.353-140delT, XM_011529971.1:c.311delT, XM_011529972.1:c.454delT, XM_011547541.1:c.155delT, XM_011547750.1:c.311delT, XM_011547751.1:c.238delT, XM_011547756.1:c.-951delA, XM_011548819.1:c.155delT, XP_005278411.1:p.Val52Glyfs, XP_011528268.1:p.Trp152Glyfs, XP_011528269.1:p.Trp152Glyfs, XP_011528270.1:p.Trp152Glyfs, XP_011528271.1:p.Val104Glyfs, XP_011528273.1:p.Val104Glyfs, XP_011528274.1:p.Trp152Glyfs, XP_011545843.1:p.Val52Glyfs, XP_011546052.1:p.Val104Glyfs, XP_011546053.1:p.Trp80Glyfs, XP_011547121.1:p.Val52Glyfs, XR_430455.2:n.-787delA, XR_952745.1:n.1611delT, rs11568727, rs28371709
A > -
A > A
indel
W152G
VIP No Clinical Annotations available No Variant Annotations available
rs5030656 NC_000022.10:g.42524176_42524178delCTT, NC_000022.11:g.42128174_42128176delCTT, NG_008376.3:g.6816_6818delAAG, NM_000106.5:c.841_843delAAG, NM_001025161.2:c.688_690delAAG, NP_000097.3:p.Lys281del, NP_001020332.2:p.Lys230del, NT_187682.1:g.50515_50517delCTT, NW_004504305.1:g.50501_50503delCTT, NW_009646208.1:g.13740_13742delCTT, XM_005278353.1:c.697_699delAAG, XM_005278354.1:c.541_543delAAG, XM_005278354.3:c.541_543delAAG, XM_011529966.1:c.841_843delAAG, XM_011529967.1:c.841_843delAAG, XM_011529968.1:c.841_843delAAG, XM_011529969.1:c.697_699delAAG, XM_011529970.1:c.688_690delAAG, XM_011529971.1:c.697_699delAAG, XM_011529972.1:c.841_843delAAG, XM_011547541.1:c.541_543delAAG, XM_011547750.1:c.697_699delAAG, XM_011547751.1:c.625_627delAAG, XM_011547756.1:c.-1861_-1859del, XM_011548819.1:c.541_543delAAG, XP_005278410.1:p.Lys233del, XP_005278411.1:p.Lys181del, XP_011528268.1:p.Lys281del, XP_011528269.1:p.Lys281del, XP_011528270.1:p.Lys281del, XP_011528271.1:p.Lys233del, XP_011528272.1:p.Lys230del, XP_011528273.1:p.Lys233del, XP_011528274.1:p.Lys281del, XP_011545843.1:p.Lys181del, XP_011546052.1:p.Lys233del, XP_011546053.1:p.Lys209del, XP_011547121.1:p.Lys181del, XR_430455.2:n.-1697_-1695del, XR_952745.1:n.1998_2000delAAG, rs587777919
CTT > -
CTT > CTT
indel
VIP No Clinical Annotations available No Variant Annotations available
rs59421388 NC_000022.10:g.42523610C>T, NC_000022.11:g.42127608C>T, NG_008376.3:g.7384G>A, NM_000106.5:c.1012G>A, NM_001025161.2:c.859G>A, NP_000097.3:p.Val338Met, NP_001020332.2:p.Val287Met, NT_187682.1:g.49949C>T, NW_004504305.1:g.49935C>T, NW_009646208.1:g.13174C>T, XM_005278353.1:c.868G>A, XM_005278354.1:c.712G>A, XM_005278354.3:c.712G>A, XM_011529966.1:c.1012G>A, XM_011529967.1:c.1012G>A, XM_011529968.1:c.1012G>A, XM_011529969.1:c.868G>A, XM_011529970.1:c.859G>A, XM_011529971.1:c.868G>A, XM_011529972.1:c.870G>A, XM_011547541.1:c.*118G>A, XM_011547750.1:c.868G>A, XM_011547751.1:c.796G>A, XM_011548819.1:c.*118G>A, XP_005278410.1:p.Val290Met, XP_005278411.1:p.Val238Met, XP_011528268.1:p.Val338Met, XP_011528269.1:p.Val338Met, XP_011528270.1:p.Val338Met, XP_011528271.1:p.Val290Met, XP_011528272.1:p.Val287Met, XP_011528273.1:p.Val290Met, XP_011528274.1:p.Thr290=, XP_011546052.1:p.Val290Met, XP_011546053.1:p.Val266Met, XR_952745.1:n.2027G>A
C > T
SNP
V338M
VIP No Clinical Annotations available No Variant Annotations available
rs61736512 NC_000022.10:g.42525134C>T, NC_000022.11:g.42129132C>T, NG_008376.3:g.5860G>A, NM_000106.5:c.406G>A, NM_001025161.2:c.353-188G>A, NP_000097.3:p.Val136Met, NT_187682.1:g.51473C>T, NW_004504305.1:g.51459C>T, NW_009646208.1:g.14698C>T, XM_005278353.1:c.363-189G>A, XM_005278354.1:c.107G>A, XM_005278354.3:c.107G>A, XM_011529966.1:c.406G>A, XM_011529967.1:c.406G>A, XM_011529968.1:c.406G>A, XM_011529969.1:c.263G>A, XM_011529970.1:c.353-188G>A, XM_011529971.1:c.263G>A, XM_011529972.1:c.406G>A, XM_011547541.1:c.107G>A, XM_011547750.1:c.263G>A, XM_011547751.1:c.190G>A, XM_011547756.1:c.-903C>T, XM_011548819.1:c.107G>A, XP_005278411.1:p.Arg36His, XP_011528268.1:p.Val136Met, XP_011528269.1:p.Val136Met, XP_011528270.1:p.Val136Met, XP_011528271.1:p.Arg88His, XP_011528273.1:p.Arg88His, XP_011528274.1:p.Val136Met, XP_011545843.1:p.Arg36His, XP_011546052.1:p.Arg88His, XP_011546053.1:p.Val64Ile, XP_011547121.1:p.Arg36His, XR_430455.2:n.-739C>T, XR_952745.1:n.1563G>A
C > T
SNP
V136M
No VIP available CA VA
rs951439 NC_000001.10:g.163033691C>T, NC_000001.11:g.163063901C>T, NG_023312.1:g.296C>T, rs36214199, rs386623110, rs52799590, rs57153444
C > T
SNP
No VIP available No Clinical Annotations available VA
rs9952628 NC_000018.10:g.47228280G>A, NC_000018.9:g.44754651G>A, NM_001278063.1:c.2917+2179C>T, XM_006722525.2:c.2917+2179C>T, rs17785317, rs59209153
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Chlorperphenazine
  • Etaperazin
  • Etaperazine
  • Ethaperazine
  • PZC
  • Perfenazina
  • Perfenazine
  • Perphenazin
Trade Names
  • Apo-Perphenazine
  • Decentan
  • Emesinal
  • Etrafon-A
  • Etrafon-Forte
  • F-Mon
  • Fentazin
  • Perphenan
  • Thilatazin
  • Trifaron
  • Trilafon
  • Trilifan
  • Triphenot
Brand Mixture Names
  • Apo Peram Tab 2-25 (Amitriptyline Hydrochloride + Perphenazine)
  • Apo Peram Tab 3-15 (Amitriptyline Hydrochloride + Perphenazine)
  • Elavil Plus Tab (Amitriptyline Hydrochloride + Perphenazine)
  • Etrafon 2 10 (Amitriptyline Hydrochloride + Perphenazine)
  • Etrafon D Tab (Amitriptyline Hydrochloride + Perphenazine)
  • Etrafon F Tab (Amitriptyline Hydrochloride + Perphenazine)
  • Etrafon a Tab (Amitriptyline Hydrochloride + Perphenazine)
  • Pms-Levazine 2/25 Tab (Amitriptyline Hydrochloride + Perphenazine)
  • Pms-Levazine 3/15 Tab (Amitriptyline Hydrochloride + Perphenazine)
  • Pms-Levazine 4/25 Tab (Amitriptyline Hydrochloride + Perphenazine)
  • Proavil Tab (Amitriptyline Hydrochloride + Perphenazine)
  • Triavil Tab (Amitriptyline Hydrochloride + Perphenazine)

PharmGKB Accession Id

PA450882

Type(s):

Drug

Description

An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.

Source: Drug Bank

Indication

For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone and vomiting centre. Perphenazine also binds the alpha andrenergic receptor. This receptor's action is mediated by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.

Source: Drug Bank

Pharmacology

Perphenazine is a piperazinyl phenothiazine, acts on the central nervous system, and has a greater behavioral potency than other phenothiazine derivatives whose side chains do not contain a piperazine moiety. It is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Perphenazine is 10 to 15 times as potent as chlorpromazine; that means perphenazine is a highly potent antipsychotic. In equivalent doses it has approximately the same frequency and severity of early and late extrapypramidal side-effects compared to Haloperidol.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.|Take with food.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic.

Source: Drug Bank

Absorption

Absolute bioavailability is 40% following oral administration.

Source: Drug Bank

Half-Life

8-12 hours, but ranges up to 20 hours.

Source: Drug Bank

Toxicity

Symptoms of overdose include stupor or coma, and children may have convulsive seizures. Signs of arousal may not occur for 48 hours. Oral LD 50=318 mg/kg (rat); IPR LD 50=64 mg/kg (mouse)

Source: Drug Bank

Route of Elimination

Perphenazine is extensively metabolized in the liver to a number of metabolites by sulfoxidation, hydroxylation, dealkylation, and glucuronidation.

Source: Drug Bank

Chemical Properties

Chemical Formula

C21H26ClN3OS

Source: Drug Bank

Isomeric SMILES

c1ccc2c(c1)N(c3cc(ccc3S2)Cl)CCCN4CCN(CC4)CCO

Source: OpenEye

Canonical SMILES

OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1

Source: Drug Bank

Average Molecular Weight

403.969

Source: Drug Bank

Monoisotopic Molecular Weight

403.148510866

Source: Drug Bank

SMILES

OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1

Source: Drug Bank

InChI String

InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ADRA1A (source: Drug Bank )
CALM1 (source: Drug Bank )
CALM3 (source: Drug Bank )
CYP2D6 (source: Drug Bank )
DRD1 (source: Drug Bank )
DRD2 (source: Drug Bank )

Drug Interactions

Interaction Description
atomoxetine - perphenazine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank )
bromocriptine - perphenazine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank )
bromocriptine - perphenazine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank )
cisapride - perphenazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
cisapride - perphenazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
dexfenfluramine - perphenazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
diethylpropion - perphenazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
donepezil - perphenazine Possible antagonism of action (source: Drug Bank )
donepezil - perphenazine Possible antagonism of action (source: Drug Bank )
fenfluramine - perphenazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
fenfluramine - perphenazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
galantamine - perphenazine Possible antagonism of action (source: Drug Bank )
galantamine - perphenazine Possible antagonism of action (source: Drug Bank )
gatifloxacin - perphenazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
gatifloxacin - perphenazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
grepafloxacin - perphenazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
grepafloxacin - perphenazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
guanethidine - perphenazine The agent decreases the effect of guanethidine (source: Drug Bank )
guanethidine - perphenazine Perphenazine may decrease the effect of guanethidine. (source: Drug Bank )
levofloxacin - perphenazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
levofloxacin - perphenazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
mazindol - perphenazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
mazindol - perphenazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - amphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - amphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank )
perphenazine - atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank )
perphenazine - benzphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - benzphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - bromocriptine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank )
perphenazine - bromocriptine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank )
perphenazine - cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - dexfenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - dexfenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - dextroamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - dextroamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - diethylpropion Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - diethylpropion Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - donepezil Possible antagonism of action (source: Drug Bank )
perphenazine - donepezil Possible antagonism of action (source: Drug Bank )
perphenazine - fenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - fenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - galantamine Possible antagonism of action (source: Drug Bank )
perphenazine - galantamine Possible antagonism of action (source: Drug Bank )
perphenazine - gatifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - gatifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - grepafloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - grepafloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - guanethidine The agent decreases the effect of guanethidine (source: Drug Bank )
perphenazine - guanethidine Perphenazine may decrease the effect of guanethidine. (source: Drug Bank )
perphenazine - levofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - levofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - mazindol Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - mazindol Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - methamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - methamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - metrizamide Increased risk of convulsions (source: Drug Bank )
perphenazine - metrizamide Increased risk of convulsions (source: Drug Bank )
perphenazine - phendimetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - phendimetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - phenmetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - phenmetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - phentermine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - phentermine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - phenylpropanolamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - phenylpropanolamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
perphenazine - rivastigmine Possible antagonism of action (source: Drug Bank )
perphenazine - rivastigmine Possible antagonism of action (source: Drug Bank )
perphenazine - sparfloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - sparfloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
perphenazine - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
phentermine - perphenazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
phenylpropanolamine - perphenazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
tacrine - perphenazine The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Perphenazine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents. (source: Drug Bank )
tacrine - perphenazine The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Perphenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents. (source: Drug Bank )
terfenadine - perphenazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
terfenadine - perphenazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
tetrabenazine - perphenazine May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. (source: Drug Bank )
trazodone - perphenazine The 2D6 inhibitor, Trazodone, may increase the efficacy of Perphenazine by decreasing Perphenazine metabolism and clearance. Monitor for changes in Perphenazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank )
trazodone - perphenazine The 2D6 inhibitor, Trazodone, may increase the efficacy of Perphenazine by decreasing Perphenazine metabolism and clearance. Monitor for changes in Perphenazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank )
trimethobenzamide - perphenazine Trimethobenzamide and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank )
triprolidine - perphenazine The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Perphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank )
triprolidine - perphenazine The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Perphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank )
trospium - perphenazine Trospium and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to perphenazine: 14

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450-mediated drug metabolism in the brain. Journal of psychiatry & neuroscience : JPN. 2012. Miksys Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic testing and molecular biomarkers. 2012. Müller Daniel J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study. Pharmacogenomics. 2012. Liu Qian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study of antipsychotic-induced QTc interval prolongation. The pharmacogenomics journal. 2010. Aberg K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2D6. Pharmacogenetics and genomics. 2009. Owen Ryan P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biological psychiatry. 2008. Campbell Daniel B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenetics and genomics. 2007. Aklillu Eleni, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?. Clinical pharmacokinetics. 2002. Dahl Marja-Liisa. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Science, medicine, and the future: Pharmacogenetics. BMJ (Clinical research ed.). 2000. Wolf C R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clinical pharmacokinetics. 1997. Sproule B A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clinical pharmacology and therapeutics. 1996. Linnet K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clinical pharmacology and therapeutics. 1996. Jerling M, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0781-1046-01
DrugBank:
DB00850
ChEBI:
8028
KEGG Compound:
C07427
KEGG Drug:
D00503
PubChem Compound:
4748
PubChem Substance:
148869
46507058
IUPHAR Ligand:
209
Drugs Product Database (DPD):
726184
ChemSpider:
4586
Therapeutic Targets Database:
DAP000100
FDA Drug Label at DailyMed:
6c76e98d-b8c3-441f-bac5-a9de6dc8f14f

Clinical Trials

These are trials that mention perphenazine and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.